CTRI/2019/11/022130尚未招募2 期
Phase -II,Non-randomized, Open label,single arm study on Siddha medicine Thulasi ennai in the treatment of soolikanam(childhood bronchial asthma) among 6-12 years of age. - THULASI
S Sonitha0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Cough without expectoration
- •Running nose
- •chest tightness
排除标准
- •Primary complex
- •Hypersensitivity pneumonitis
- •Lung abscess
- •Cystic fibrosis
- •Bronchiolitis
研究者
相似试验
进行中（未招募）
1 期
Olaparib in Patients With Advanced Cancers Who Have A Confirmed Genetic BRCA1 And/Or BRCA2 MutatioPatients With Advanced Cancers Who Have A Confirmed Genetic BRCA1 And/Or BRCA2 MutationMedDRA version: 14.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022278-15-SEAstraZeneca AB300
进行中（未招募）
1 期
A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy And Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have A Confirmed Genetic BRCA1 And/Or BRCA2 Mutation. ?Ensayo Fase II Multicéntrico, Abierto, No Aleatorizado, No Comparativo, para Evaluar la Eficacia y Seguridad de Olaparib Administrado por Vía Oral Dos Veces al Día en Pacientes con Tumores Avanzados que Presentan una Mutación en BRCA1 y/o BRCA2.?EUCTR2010-022278-15-ESAstraZeneca AB300
进行中（未招募）
1 期
Olaparib in Patients With Advanced Cancers Who Have A Confirmed Genetic BRCA1 And/Or BRCA2 MutatioEUCTR2010-022278-15-DEAstraZeneca AB300
进行中（未招募）
不适用
Phase II multicente, non randomized, open label trial of nivolumab in combination with ipilimumab in subjects with previously untreated metastatic uveal melanoma.EUCTR2015-004429-15-ESGRUPO ESPAÑOL MULTICISPLINAR DE MELANOMA
进行中（未招募）
1 期
A Phase II clinical trial to asses efficacy and safety of DARC methodology (Detection of Apoptosing Retinal Cells) in visualising the death of retinal cells in healthy volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis.Glaucoma, Age-related Macular Degeneration, and Optic Neuritis.MedDRA version: 19.0 Level: LLT Classification code 10047560 Term: Visual field perimetric tests System Organ Class: 10022891 - InvestigationsMedDRA version: 19.0 Level: HLGT Classification code 10018307 Term: Glaucoma and ocular hypertension System Organ Class: 10015919 - Eye disordersMedDRA version: 19.0 Level: LLT Classification code 10021948 Term: Infiltration intravenous injection System Organ Class: 100000004867MedDRA version: 19.0 Level: PT Classification code 10057208 Term: Optical coherence tomography System Organ Class: 10022891 - InvestigationsMedDRA version: 19.0 Level: PT Classification code 10071129 Term: Neovascular age-related macular degeneration System Organ Class: 10015919 - Eye disordersMedDRA version: 19.0 Level: PT Classification code 10064930 Term: Age-related macular degeneration System Organ Class: 10015919 - Eye disordersMedDRA version: 19.0 Level: PT Classification code 10047566 Term: Visual field tests System Organ Class: 10022891 - InvestigationsMedDRA version: 19.0 Level: LLT Classification code 10009034 Term: Chronic open angle glaucoma System Organ Class: 10015919 - Eye disordersEUCTR2016-002531-15-GBCL Comprehensive Clinical Trials Unit113